PTC Therapeutics, a US-based drugs developer for muscles, plans to float on the Nasdaq stock exchange with a market capitalisation of about $322m.
PTC plans to offer 6.9 million shares at between $13 and $16 each.
PTC posted a $26m net loss on $34m in revenue for last year, compared to $30m in net income on $105m in revenue for 2011.
Investment banks JP Morgan and Credit Suisse are PTC’s lead underwriters for the initial public offering (IPO), with legal…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
